Eine mögliche Zulassung neuer monoklonaler Antikörpertherapien für die Alzheimer-Krankheit stellt die Gesundheitssysteme weltweit vor Herausforderungen. In der vorliegenden Arbeit werden durch den Verein Swiss Memory Clinics (SMC) eine Analyse der vorhandenen Ressourcen vorgenommen und mögliche Versorgungsengpässe identifiziert. Die Bewältigung möglicher Kapazitätsengpässe stellt eine Herausforderung dar, die Massnahmen auf verschiedenen Ebenen erfordert. Unsere Analyse zeigt aber auch auf, dass wir in der Schweiz über gute Voraussetzungen verfügen, neue Entwicklungen in die bestehenden Versorgungsstrukturen zu integrieren.

Schlüsselwörter: Alzheimer-Krankeit, Demenz, Therapie, Versorgung

Hintergrund

Aktuell leben rund 156 900 Menschen mit Demenz in der Schweiz, im Jahr 2050 werden dies voraussichtlich 315 000 Menschen sein. Jährlich kommt es zu 33 800 neu dia­gnostizierten Demenzen (1). SMC engagiert sich seit seiner Gründung am 20. Mai 2008 schweizweit für eine qualitativ hochstehende und breit verfügbare Diagnose- und Behandlungsqualität neurokognitiver Störungen – insbesondere der verschiedenen Demenzformen (2, 3, 4, 5).

Anti-Amyloid-Therapien (AAT) sind in der Schweiz bisher nicht zugelassen. Zwei Phase-3-Studien mit den monoklonalen Antikörpern Lecanemab (6) und Donanemab (7) haben bei der Behandlung der leichten kognitiven Störung (MCI) und der leichten Demenz bei Alzheimer-Krankheit (AK) über einen Zeitraum von 18 Monaten signifikante positive Ergebnisse in allen klinischen und paraklinischen (bspw. Lebensqualität) Endpunkten zeigen können. Die Medikamente werden bereits in einigen Ländern (z.B. USA, Japan, China) eingesetzt. Die Australische Zulassungsbehörde hat sich gegen eine Zulassung von Lecanemab ausgesprochen. In Grossbritannien hat sich die Zulassungsbehörde unter Ausschluss der Personen mit dem höchsten Risiko für Nebenwirkungen für eine Zulassung ausgesprochen, aber das National Institute for Health and Care Excellence hat sich aus medizinisch-ökonomischen Gründen gegen eine Kostenübernahme durch den National Health Service ausgesprochen. Auch die Europäische Arzneimittelbehörde (EMA) hat sich schliesslich nach einem Reevaluationsverfahren am 14.11.2024 unter Ausschluss der Personen mit dem höchsten Risiko für Nebenwirkungen für eine Zulassung von Lecanemab ausgesprochen. In der Schweiz durchlaufen die Präparate aktuell das Zulassungsverfahren bei Swissmedic.

Die AAT erfordern bezüglich Diagnostik, Applikation der Therapien und Monitoring zahlreiche Ressourcen des Gesundheitssystems. Eine Analyse von Hlavka et al. in sechs europäischen Ländern zeigt auf, dass Kapazitätsengpässe dazu führen könnten, dass über eine Million Patientinnen und Patienten mit einer leichten kognitiven Störung aufgrund einer Alzheimer-Krankheit in das Stadium einer Demenz fortschreiten könnten, während sie auf einer Warteliste für eine spezialisierte Behandlung stehen (8). Diese Zahl fällt allerdings deutlich zu hoch aus, da wir mittlerweile wissen, dass nur eine Minderheit der infrage kommenden Population für die AAT geeignet ist (siehe unten).
Im Folgenden möchten wir ausführen, wie gut nach unserer Einschätzung das Schweizer Gesundheitssystem die Einführung einer solchen Therapie bewerkstelligen könnte.

Überblick Swiss Memory Clinics (SMC)

Die im Folgenden aufgeführten Angaben beruhen mehrheitlich auf einer Mitgliederumfrage des Vereins SMC zwecks Erfassung struktureller und prozeduraler Merkmale der interdisziplinären Behandlung.

Hausärztinnen und Hausärzte sind häufig die erste Anlaufstelle für die Patientinnen und Patienten und deren Angehörigen und funktionieren als Hauptzuweisende für die Diagnostik und Therapie in den Memory Clinics (MC). Die Abläufe dieser Zusammenarbeit wurden im Rahmen der SMC Diagnostikempfehlungen im Sinne einer «Case finding»-Strategie beschrieben (3, 4).

Die Schweiz hat mit ca. 5.44 MCs pro 1 000 000 Einwohner eine im internationalen Vergleich hohe Dichte an spezialisierten interdisziplinären Versorgungseinheiten. Hinzu kommen Angebote ausserhalb des SMC-Netzwerks.

Die folgende Tab. 1 orientiert über die Entwicklung innerhalb des SMC-Netzwerks von 2018 bis 2023. Es lässt sich eine klare Zunahme der Anzahl an MC sowie der Personalressourcen pro MC festhalten bei allerdings gleichzeitig ansteigenden Wartezeiten.

Verfügbarkeit Diagnostik
Der Zugang zur Diagnostik ist insgesamt sehr gut. Neuropsychologische Untersuchungen pro MC und pro Jahr werden in 83 % aller Fälle durchgeführt. Alle MC haben innerhalb ihrer Institution oder über Kooperationen Zugang zu Laboruntersuchungen, MRI, FDG-PET, Liquordiagnostik und EEG, 89 % auch zu Amyloid-PET.

Diagnoseverteilung
Die Verteilung der Diagnosen im Jahr 2023 wird in der Abbildung 1 dargestellt. Die Angaben basieren auf Schätzungen. In 65 % aller Fälle wird eine AK festgestellt. In 39 % der Fälle werden die Diagnosen MCI oder leichte Demenz bei AK gestellt.

Potenzielle Versorgungslücke im Kontext von AAT

Trotz der relativ hoch entwickelten Schweizer Infrastruktur im Hinblick auf die Versorgung von Demenzbetroffenen stellt sich die Frage, inwieweit durch die Zulassung einer AAT eine Versorgungslücke entstehen könnte. Hier gibt es noch einige Unbekannte, beispielsweise liegen noch wenige Daten zu klinischen Langzeiteffekten und zur Sicherheit bei längerer Anwendung vor. Dennoch ist bereits jetzt eine Einschätzung erforderlich, um abzuschätzen, ob die Schweiz in der Lage sein wird, diese Behandlungen zeitgerecht bereitzustellen.

Diagnostik
In der Schweiz wird von einer jährlichen Inzidenzrate von 32 900 Demenzerkrankungen ausgegangen. In den MC werden ca. 15 000 Fälle pro Jahr abgeklärt. Im Falle zunehmender Zuweisungen zur Frühdiagnostik im Kontext der neuen Therapiemöglichkeiten gehen die MC davon aus, dass durch Effizienzsteigerung und Ausbau der Angebote schätzungsweise 3000 zusätzliche Abklärungen schweizweit pro Jahr durchgeführt werden könnten.
Eine graduelle Erhöhung der Nachfrage an MC-Abklärungen auf 20 000 bis 25 000 pro Jahr (60–75 % der Jahresinzidenz) ist ein realistisches Szenario, was zunächst zu längeren Wartezeiten bis zur Erstabklärung führen könnte.

Therapie
Erste Daten aus der Versorgung zeigen, dass angesichts der aktuellen Anwendungsempfehlungen zum Einsatz der neuen Substanzen in einer AK-Population in den MC je nach angewandten Ein- und Ausschlusskriterien möglicherweise nur ca. 8 bis 17 % der Fälle für eine AAT infrage kommen (9, 10, 11). Für die MC in der Schweiz würde das aktuell bei einer Population mit beginnender AK von ca. 5850 Fällen (39 % der 15 000 MC-Fälle) näherungsweise 468 bis 995 potenzielle neue AAT-Patientinnen und -Patienten pro Jahr bedeuten. Diese Zahl könnte in der Folge zunehmender Frühdiagnostik im Verlauf ansteigen (siehe oben). Wie viele hiervon sich dann tatsächlich für eine Therapie entscheiden, kann gegenwärtig noch nicht abgeschätzt werden und wird stark von den Nutzen-Risiko-Bewertungen der Patientinnen und Patienten abhängen. Es ist wahrscheinlich, dass sich nur ein Bruchteil der infrage kommenden Patientinnen und Patienten auf eine AAT einlassen würde.

Ressourcen für die Durchführung von Infusionstherapien sind derzeit bei Weitem nicht in allen MC verfügbar. Inwiefern die Möglichkeit eines Aufbaus von Therapieplätzen in den MC-Netzwerken besteht, ist in 65 % noch unklar. In 32 % der MC werden 15 wöchentliche Therapieplätze direkt oder indirekt als verfügbar angezeigt, was einer durchschnittlichen Kapazität von ca. 180 Infusionstherapien pro Woche entspricht. Das ergibt in Abhängigkeit der Applikationsfrequenz eine Kapazität von jährlich 360 bis 720 AAT-Patientinnen und -Patienten. Die Infusionskapazität im MC-Netzwerk würde sich im Verlauf durch organisatorische Massnahmen und gezielte Kooperationen voraussichtlich erhöhen lassen. Darüber hinaus könnten zeitlich limitierte Anwendungen sowie sich in Entwicklung befindende subkutane Applikationsformen die Situation entlasten.

Überblick
Der antizipierte steigende Ressourcenbedarf für spezialisierte Abklärungen im Falle einer Zulassung neuer AAT steht im Kontrast zu den Ressourcenengpässen im Bereich Fachpersonal mit tendenziell steigenden Wartezeiten und der limitierten Ausbaukapazität auf ca. 18 000 Abklärungen pro Jahr. Die Schätzungen potenzieller Versorgungslücken betreffend die Kapazitäten für Infusionstherapien sind unsicher und reichen von 0 bis 635. Hier gehen wir aber längerfristig nicht von erheblichen Lücken aus. Der Zugang zur apparativen oder laborchemischen Zusatzdiagnostik scheint in der Schweiz wenig problematisch zu sein. Massnahmen, die zu einer Kompensation fehlender Ressourcen beitragen können, umfassen die Intensivierung der Kooperationen innerhalb und ausserhalb der jeweiligen Institutionen sowie diagnostische und therapeutische Weiterentwicklungen (siehe unten) (Tab. 2).

Massnahmen und Rahmenbedingungen

Aufgrund der notwendigen Fachkenntnisse, die lange Aus- und Weiterbildungszeiten erfordern, sowie dem generellen Fachkräftemangel im Gesundheitswesen erscheint eine rasche personelle Aufstockung zum Ausgleich der Versorgungslücke unrealistisch. Kontinuierliche Verbesserungsprozesse zur Erhöhung der Produktivität der bestehenden Fachkräfte wie Digitalisierung oder Delegation sowie das Eingehen von Kooperationen erscheinen zielführender. Zentral wird es sein, inwiefern eine präzise und effiziente Indikationsstellung bei schlanken Abklärungsprozessen gelingt und die Infusionskapazitäten ausgeweitet werden können. Hierzu sind unter anderem folgende Aspekte zu berücksichtigen:

• Nutzung neuer Biomarkertechnologien, wie z. B. Blutbiomarker und Augmentation durch künstliche Intelligenz
• Neue Formen der Zusammenarbeit zwischen der Grundversorgung und den MC
• Auf- und Ausbau von Infusionskapazitäten durch gezielte Kooperationen
• Zeitlich limitierte und subkutane Applikationsformen
• Effizientes Management möglicher Nebenwirkungen durch gezielte Kooperationen

Notwendige Rahmenbedingungen:

• Zentrale koordinierende Rolle der Demenzexpertinnen und -experten zur Sicherstellung der Behandlungs- und Indikationsqualität sowie hoher Stellenwert der sorgfältigen und patientenzentrierten Aufklärung sowie medizinethischer Aspekte
• Fachempfehlungen betreffend geeignete Diagnostik und Therapie sowie Erstellung von standardisierten Abläufen (Standard Operation Procedures)
• Verbesserte Datengrundlagen mittels Förderung der Versorgungsforschung sowie Entwicklung eines Registers
• Einheitliche Vorgehensweise bezüglich Kostengutspracheprozess für den Zeitraum zwischen einem allfälligen positiven Entscheid der Swissmedic und der Aufnahme auf die Spezialitätenliste

Schlussfolgerungen

Das Schweizer Gesundheitswesen wird nicht ohne Weiteres in der Lage sein, im Falle einer Zulassung einer AAT allen Patientinnen und Patienten innerhalb eines angemessenen Zeitraums den Zugang zu ermöglichen. Wichtige Anpassungen werden erforderlich sein. In Anbetracht unserer Analyse zeigt sich aber auch, dass wir über Strukturen und Massnahmen verfügen, um das Risiko zu minimieren, dass Patientinnen und Patienten ein Fortschreiten der Erkrankung erfahren, während sie auf eine spezialisierte Behandlung warten.

Die Bewältigung möglicher Kapazitätsengpässe stellt eine Herausforderung dar, die Massnahmen auf verschiedenen Ebenen erfordert. Insbesondere mangelnde personelle ­Ressourcen erschweren die Umsetzung des Auf- und Ausbaus weiterer Angebote. Hier sind Politik (national und kantonal), Universitäten, Spitäler/Kliniken, Fachgesellschaften, Weiterbildungsstätten und Führungskräfte gefordert.
Die Autorinnen und Autoren sind der Ansicht, dass im Fall einer Zulassung der Zugang zur AAT allen geeigneten und interessierten Patientinnen und Patienten ermöglicht werden sollte.

Key Messages
• Die (mögliche) Zulassung neuer monoklonaler Antikörpertherapien für die Alzheimer-Krankheit stellt die Gesundheitssysteme vor Herausforderungen, auch in der Schweiz.
• Unsere Analyse zeigt auf, dass wir in der Schweiz über gute Voraussetzungen verfügen, neue Entwicklungen in die bestehenden Versorgungsstrukturen zu integrieren.
• Im Fall einer Zulassung sollte der Zugang zur AAT allen geeigneten und interessierten Patientinnen und Patienten ermöglicht werden.

Abkürzungen
SMC Verein Swiss Memory Clinics
AAT Anti-Amyloid-Therapie
MCI Leichte kognitive Störung
AK Alzheimer-Krankheit
MC Memory Clinics
FTLD Frontotemporale Lobärdegeneration
LBD Lewy Body Disease
SCD Subjective Cognitive Declin

---

Version française

L’ autorisation éventuelle de nouvelles thérapies à base d’ anticorps monoclonaux pour la maladie d’ Alzheimer pose des défis aux systèmes de santé du monde entier. Dans le présent travail, l’ association Swiss Memory Clinics (SMC) procède à une analyse des ressources disponibles et identifie les éventuels points de tension dans leur déploiement. La gestion d’ éventuelles limitations en matière de capacités représente un défi qui nécessite des mesures à différents niveaux. Notre analyse montre aussi que nous disposons en Suisse de bonnes conditions pour intégrer de nouveaux développements dans les structures de soins existantes.

Mots clés: Maladie d’ Alzheimer, démence, thérapie, soins

Contexte

Actuellement, environ 156 900 personnes vivent avec une démence en Suisse, et ce chiffre devrait atteindre 315 000 personnes en 2050. Chaque année, 33 800 nouvelles démences sont diagnostiquées (1). Depuis sa création le 20 mai 2008, la SMC s’ engage dans toute la Suisse en faveur d’ un diagnostic et d’ un traitement de haute qualité et largement disponible des troubles neurocognitifs – en particulier des différentes formes de démence (2, 3, 4, 5).

Les thérapies anti-amyloïdes (AAT) ne sont pas encore disponibles en Suisse. Deux études de phase 3 avec les anticorps monoclonaux lecanemab (6) et donanemab (7) ont pu montrer des résultats positifs significatifs sur tous les critères d’ évaluation cliniques et paracliniques (p. ex. qualité de vie) dans le traitement des troubles cognitifs légers (MCI) et de la démence légère de la maladie d’ Alzheimer (MA) sur une période de 18 mois. Ces médicaments sont déjà utilisés dans certains pays (par exemple aux États-Unis, au Japon et en Chine). L’ Agence australienne des mèdicaments s’ est prononcée contre l’ autorisation du lecanemab. En Grande-Bretagne, l’ autorité d’ homologation s’ est prononcée en faveur d’ une autorisation en excluant les personnes présentant le plus grand risque d’ effets secondaires, mais le National Institute for Health and Care Excellence s’ est prononcé contre une prise en charge par le National Health Service pour des raisons médico-économiques. L’ Agence européenne des médicaments (EMA) s’ est elle aussi finalement prononcée en faveur d’ une autorisation du lecanemab après une procédure de réévaluation le 14 novembre 2024, en excluant les personnes présentant le plus grand risque d’ effets secondaires. En Suisse, les préparations sont actuellement soumises à la procédure d’ autorisation auprès de Swissmedic.
Les AAT nécessitent de nombreuses ressources du système de santé en ce qui concerne le diagnostic, l’ application des thérapies et le monitoring. Une analyse de Hlavka et al. menée dans six pays européens montre que des limitations au niveau des capacités pourraient conduire à ce que plus d’ un million de patients souffrant de troubles cognitifs légers dus à la MA évoluent vers le stade de la démence, alors qu’ ils sont sur une liste d’ attente pour un traitement spécialisé (8). Ce chiffre est toutefois nettement surestimé, car nous savons désormais que seule une minorité de la population éligible est susceptible de bénéficier de l’ AAT (voir ci-dessous).
Nous aimerions expliquer ci-dessous dans quelle mesure nous estimons que le système de santé suisse pourrait gérer l’ introduction d’ une telle thérapie.

Aperçu des Swiss Memory Clinics (SMC)

Les données présentées ci-après reposent pour la plupart sur une enquête menée par l’ association SMC auprès de ses membres afin de recenser les caractéristiques structurelles et procédurales du traitement interdisciplinaire.

Les médecins de famille sont souvent le premier point de contact pour les patients et leurs proches et fonctionnent comme les principaux référents pour le traitement dans les cliniques de la mémoire (MC). Les processus de cette collaboration ont été décrits dans le cadre des recommandations diagnostiques SMC au sens d’ une stratégie de « case finding » (3, 4).

Avec environ 5.44 MC pour 1 000 000 d’ habitants, la Suisse présente une densité élevée d’ unités de soins interdisciplinaires spécialisées en comparaison internationale. S’ y ajoutent des offres en dehors du réseau SMC.

Le tab. 1 ci-dessous présente l’ évolution au sein du réseau SMC entre 2018 et 2023. On constate une nette augmentation du nombre de MC et des ressources en personnel par MC accompagnée d’ une augmentation des délais d’ attente.

Disponibilité du diagnostic
L’ accès au diagnostic est globalement très bon. Des examens neuropsychologiques par MC et par an sont réalisés dans 83 % des cas. Tous les MC ont accès, au sein de leur institution ou par le biais de coopérations, aux examens de laboratoire, à l’ IRM, au FDG-PET, au diagnostic du LCR et à l’ EEG, 89 % ont également accès au PET amyloïde.

Répartition des diagnostics
La répartition des diagnostics en 2023 est présentée dans la fig. 1. Les données sont basées sur des estimations. Une MA représente 65 % des cas. Dans 39 % la MA est un stade de MCI ou de démence légère.

Manque potentiel de soins dans le contexte de l’ AAT

Malgré l’ infrastructure suisse relativement développée en ce qui concerne les soins aux personnes atteintes de démence, la question se pose de savoir dans quelle mesure l’ autorisation d’ une AAT pourrait entraîner une limite dans la trajectoire des soins. Il y a encore quelques inconnues à ce sujet, par exemple on dispose encore de peu de données sur les effets cliniques à long terme et sur la sécurité en cas d’ utilisation prolongée. Néanmoins, une évaluation est d’ ores et déjà nécessaire pour estimer si la Suisse sera en mesure de fournir ces traitements en temps voulu.

Diagnostic
En Suisse, on estime que le taux d’ incidence annuel des démences est de 32 900. Environ 15 000 cas sont examinés chaque année dans les MC. En cas d’ augmentation des orientations vers le diagnostic précoce dans le contexte des nouvelles possibilités thérapeutiques, les MC estiment que l’ amélioration de l’ efficacité et l’ extension de l’ offre permettraient de réaliser 3000 examens supplémentaires par an dans toute la Suisse.

Une augmentation progressive de la demande de bilans MC jusqu’ à 20 000 à 25 000 par an (60–75 % de l’ incidence annuelle) est un scénario réaliste, ce qui pourrait dans un premier temps avoir une influence négative sur les délais d’ attente jusqu’ au premier bilan.

Traitement
Les premières données issues de la prise en charge montrent que, compte tenu des recommandations actuelles d’ utilisation des nouvelles substances dans une population de MA dans les MC, seuls environ 8 à 17 % des cas pourraient éventuellement être éligibles pour une AAT, selon les critères d’ inclusion et d’ exclusion appliqués (9, 10, 11). Pour les MC en Suisse, cela signifierait actuellement, pour une population initiale de MA d’ environ 5850 cas (39 % des 15 000 cas de MC), approximativement 468 à 995 nouveaux patients éligibles pour une AAT par an. Ce nombre pourrait augmenter au fur et à mesure que le diagnostic précoce se développe (voir ci-dessus). Il n’ est pas encore possible d’ estimer combien d’ entre eux consentiront effectivement pour un traitement et cela dépendra fortement des évaluations du rapport bénéfice/risque des groupes d’ intérêt concernés. Il est probable que seule une fraction des patients éligibles accepterait de suivre une AAT.

Les ressources pour la mise en œuvre de thérapies par perfusion sont loin d’ être disponibles dans toutes les MC. Dans 65 % des cas, on ne sait pas encore dans quelle mesure il est possible d’ implémenter des places de thérapie dans les réseaux MC. Dans 32 % des MC, 15 places de thérapie hebdomadaires sont directement ou indirectement indiquées comme disponibles, ce qui correspond à une capacité moyenne d’ environ 180 thérapies par perfusion par semaine. En fonction de la fréquence d’ application, cela donne une capacité annuelle de 360 à 720 patients AAT. La capacité de perfusion dans le réseau MC pourrait vraisemblablement être augmentée au fil du temps par des mesures organisationnelles et des coopérations ciblées. En outre, une durée de traitement limitée dans le temps ainsi que des formes d’ application sous-cutanées en cours de développement pourraient améliorer la situation.

Aperçu
L’ augmentation anticipée des besoins en ressources pour les examens spécialisés en cas d’ autorisation de nouvelles AAT contraste avec les pénuries de ressources dans le domaine du personnel spécialisé, avec une tendance à l’ augmentation des temps d’ attente et une capacité d’ extension limitée à environ 18 000 de bilans par an. Les estimations des lacunes potentielles en matière de capacités pour les thérapies par perfusion sont incertaines et vont de 0 à 635. Nous ne prévoyons toutefois pas de lacunes importantes à long terme. L’ accès aux diagnostics complémentaires par appareillage ou par chimie de laboratoire semble poser peu de problèmes à la Suisse. Les mesures qui peuvent contribuer à compenser le manque de ressources comprennent l’ intensification des coopérations à l’ intérieur et à l’ extérieur des institutions respectives ainsi que les développements diagnostiques et thérapeutiques (voir ci-dessous, Tab. 2).

Mesures et conditions-cadres

En raison des connaissances spécialisées nécessaires, qui requièrent de longues périodes de formation et de perfectionnement, ainsi que de la pénurie générale de personnel qualifié dans le secteur de la santé, une augmentation rapide du personnel pour compenser le manque de soins semble irréaliste. Des processus d’ amélioration continue visant à augmenter la productivité des professionnels existants, tels que la numérisation ou la délégation, ainsi que la mise en place de coopérations semblent plus appropriés. Il sera essentiel de savoir dans quelle mesure il sera possible de poser des indications précises et efficaces avec des processus d’ évaluation allégés et d’ étendre les capacités de perfusion. Les aspects suivants doivent notamment être pris en compte :

• Utilisation de nouvelles technologies de biomarqueurs, comme les biomarqueurs sanguins et l’ augmentation par l’ intelligence artificielle.
• Nouvelles formes de collaboration entre les soins primaires et les MC.
• Mise en place et développement de capacités de perfusion par des coopérations ciblées.
• Formes d’ administration limitées dans le temps et par voie sous-cutanée.
• Gestion efficace des effets secondaires potentiels grâce à des coopérations ciblées.

Conditions cadres nécessaires :

• Rôle central de coordination des experts en démence pour garantir la qualité du traitement et de l’ indication, et grande importance accordée à une information minutieuse et centrée sur le patient ainsi qu’ aux aspects médico-éthiques.
• Recommandations professionnelles concernant le diagnostic et le traitement appropriés ainsi que l’ élaboration de procédures opératoires standard.
• Amélioration des données de base par la promotion de la recherche sur les soins et le développement d’ un registre.
• Procédure uniforme de garantie de prise en charge des coûts pour la période entre une éventuelle décision positive de Swissmedic et l’ admission sur la liste des spécialités.

Conclusions

Le système de santé suisse ne sera pas facilement en mesure d’ offrir un accès à tous les patients dans un délai raisonnable en cas d’ autorisation d’ une AAT. Des ajustements importants seront nécessaires. Au vu de notre analyse, il apparaît toutefois que nous disposons de structures et de mesures permettant de minimiser le risque que les patientes et les patients connaissent une progression de leur maladie en attendant un traitement spécialisé.
La gestion d’ éventuelles limitations en termes de capacités constitue un défi qui nécessite des mesures à différents niveaux. Le manque de ressources en personnel, notamment, rend difficile la mise en œuvre de la création et de l’ extension d’ autres offres. La politique (nationale et cantonale), les universités, les hôpitaux/cliniques, les sociétés de discipline médicale, les établissements de formation postgraduée et les cadres sont ici sollicités.
Les auteurs sont d’ avis qu’ en cas d’ autorisation, l’ accès à l’ AAT devrait être possible pour tous les patients éligibles et intéressés.

Messages à retenir
• L’ autorisation (éventuelle) de nouvelles thérapies à base d’ anticorps monoclonaux pour la maladie d’ Alzheimer pose des défis aux systèmes de santé, aussi en Suisse.
• Notre analyse montre que nous disposons en Suisse de bonnes conditions pour intégrer de nouveaux développements dans les structures de soins existantes.
• En cas d’ autorisation l’ accès à l’ AAT devrait être possible pour tous les patients éligibles et intéressés.

Abréviations
SMC Association Swiss Memory Clinics
AAT Thérapie anti-amyloïde
MCI Trouble cognitif léger
MA Maladie d’ Alzheimer
MC Memory Clinics
FTLD Dégénérescence lobaire frontotemporale
LBD Démence à corps de Lewy
SCD Déclin cognitif subjectif

---

In Switzerland, additional vaccinations against influenza, COVID-19, Streptococcus pneumoniae and varicella zoster virus (VZV), are recommended for patients with chronic lung diseases such as COPD, asthma or interstitial lung disease, since infectious diseases often lead to exacerbation of lung diseases resulting in increased disease burden and mortality. In this review we give an overview on recommended vaccinations for patients with chronic lung diseases, also including vaccinations against pertussis and RSV, which are recommended in international guidelines. While continuous development of vaccines against S. pneumoniae has given rise to high-valency vaccines covering up to 68% of S. pneumoniae variants in individuals aged ≥65 years, vaccination rates in this age group remain low in Switzerland (<10% in 2020). Vaccination rates are higher for influenza, and particularly high-dose vaccines account for high vaccination efficacy in years of low strain matching in individuals at risk. Although mortality of COVID-19 decreased since the emergence of the first SARS-CoV-2 variant, patients with chronic lung disease are still at increased risk for exacerbation, unless vaccinated with variant-adjusted vaccines. VZV and Bordetella pertussis vaccination has also significantly countered reactivation and infection rates, respectively, and subunit vaccines against VZV show long duration. However, pertussis vaccination is still limited by its fast waning. A glimpse into the future presumes the introduction of new higher-valence vaccinations against S. pneumoniae, and several types of RSV vaccines are expected to enter the Swiss market soon.

Key words: Vaccine efficacy, chronic lung diseases, viral infections, exacerbation prevention

Introduction

Chronic lung diseases present a significant health and economic burden worldwide (1). Exacerbations of chronic lung diseases particularly pose a risk for patients with pulmonary disorders, as they can lead to functional impairment, severe pneumonia, hospitalization, and death (2). For chronic obstructive pulmonary disease (COPD), repeated acute exacerbations may lead to an accelerated decline in lung function, impaired quality of life, disease progression, and higher mortality. Thus, COPD exacerbations account for 50% to 75% of COPD-associated health care costs (3). Patients with immunosuppression and/or lung transplantation, asthma, COPD or interstitial lung disease (ILD) are at increased risk of complicated infections (2, 3). Indeed, a majority of acute exacerbations of chronic lung diseases are caused by infections, particularly viral ones (4, 5). Viral detection rates range from 22-64%, and rhinoviruses are reported to be the most commonly detected viral triggers (up to 60%), followed by influenza (up to 36%) and respiratory syncytial virus (RSV; up to 28%) with other viral infections reported less frequently (parainfluenza, human metapneumovirus [HMPV], coronaviruses, adenoviruses) (3). Bacterial co-infections, which occur in about 6-27% of cases, may prolong hospitalization even further, and lead to more severe impairments of lung function (3, 6). Thus, prevention of infections through vaccination is a key management concept to reduce acute infection-driven exacerbations and associated worsening of chronic lung disease (7). Since influenza and Streptococcus pneumoniae lead to increased hospitalization rates and mortality in patients with chronic lung diseases, current international guidelines, as well as the Swiss vaccination plan, recommend influenza and pneumococcus vaccinations in this patient group (7, 8, 9). Similarly, a vaccination against the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) is recommended for individuals at risk in Switzerland (8, 9). Reflecting the fact that other viral infections such as RSV may also contribute to exacerbations, and show similar or even high-er mortality rates than influenza, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends a vaccination with existing RSV vaccines in all patients with COPD (9, 10, 11). Correspondingly, the Federal Office of Public Health (FOPH) has most recently released a recommendation for the RSV vaccination in individuals ≥ 75 years of age and for individuals at high risk of complications, including those with chronic lung disease, above the age of 60 years (12).

This article aims to summarize data on vaccine efficacy (VE) for populations with chronic lung diseases and provides a glimpse into future vaccination options for individuals at risk.

Chronic pulmonary diseases

Chronic obstructive pulmonary disease (COPD)
COPD is the third leading cause of death worldwide, accounting for 3.23 million deaths in 2019 (7, 13). In Switzerland, around 400 000 individuals are affected by COPD (14). It is the 4th most prevalent cause of death in Switzerland, and its incidence is rising (15, 16). COPD affects smokers in particular. However, it can also develop in non-smokers and is characterized by chronic inflammation of lung tissue and loss of lung function, often caused by exacerbations (2). COPD puts a high burden on patients and healthcare systems, with exacerbations causing a decreased quality of life and a negative impact on survival prognosis. In the context of the high burden of COPD, prevention of exacerbation frequently triggered by viral infections is paramount to improve the prognosis of the disease (3).

Asthma
Asthma is a heterogeneous pulmonary inflammation characterized by fluctuating bronchial hyper-responsiveness and variable airflow obstruction. Globally, about 300 million individuals of all ages are affected. This amounts to every 14th person in Switzerland, and incidences are increasing (2, 17). According to the hygiene hypothesis, the increasing prevalence of asthma may be due to a lower incidence of infections and thus less challenges for the immune system (18). However, other theories claim that RSV or rhinovirus infection early in life may also be associated with a higher risk of developing asthma later in life (19, 20).

Interstitial lung disease (ILD)
The term ILD encompasses a wide range of fibrotic and inflammatory lung diseases, the prevalence of which is difficult to estimate due to the lack of standardized definitions (21). Thus, less evidence exists regarding the role of viral infections in the acute exacerbation of fibrotic lung disease (2). However, one report recorded a 30-day inpatient mortality of 20.6% after a viral infection in selected patients with ILD emphasizing the importance of early infection prevention also in this patient population (22). Mortality rates may however vary between different forms of ILD: for example, acute exacerbation of idiopathic pulmonary disease is associated with very high in-hospital mortality (>50%), as opposed to desquamative interstitial pneumonia, which generally comes with a better prognosis (23, 24).

Swiss Vaccination plan for the general population and specific groups

In Switzerland, there are currently 11 recommended basic vaccinations starting in childhood: tetanus, diphtheria, pertussis, poliomyelitis, Haemophilus influenzae type B, hepatitis B, S. pneumoniae, varicella zoster virus (VZV) and the trivalent vaccine against measles, mumps, and rubella. Vaccination against human papilloma virus follows in adolescence. Additional vaccinations in adulthood are recommended against herpes zoster, influenza, and pneumococcus and it is highly encouraged to stay up to date with all vaccinations according to the Swiss vaccination schedule – see link at the end of the article (8).

For at risk groups (incl. elderly and patients with cardiovascular, respiratory or other comorbidities), the Swiss vaccination plan recommends a yearly vaccination against influenza and coronavirus disease 19 (COVID-19) as well as a single dose vaccination against S. pneumoniae and a two-dose vaccination against herpes zoster for individuals aged ≥50 years depending on the classification of the lung disease (8). Indeed, COPD and asthma may be independent risk factors for herpes zoster. Since November 2024, the RSV vaccination is explicitly recommended for individuals aged ≥75 and individuals at high risk aged ≥60, in particular those with chronic lung disease (12).

International guidelines on vaccinations in COPD

The GOLD guidelines, which focus on individuals with COPD, have similar recommendations. However, they do not only emphasize the need for vaccination against influenza, COVID-19, S. pneumoniae, and herpes zoster (in individuals aged ≥50 years), but also RSV vaccination for individuals aged ≥60 years and pertussis vaccination in individuals with chronic lung diseases (9).
In the following chapter, incidences of several important infections in patients with chronic lung diseases as well as evidence for vaccination recommendations in this population will be summarized. Our review is limited to adults.

Pneumococcus vaccination

Streptococcus pneumoniae can cause parenchymal infections in many organs, particularly in the lower respiratory tract, and is a major cause of community-acquired pneumonia (CAP) (25). Exacerbations of COPD in combination with CAP are associated with reduced survival rates and an increased likelihood of subsequent exacerbations (26). Particularly, adults >65 years are affected by invasive pneumococcal disease (IPD) with highly increased incidence in those adults with at risk conditions such as asthma, COPD, and cardiovascular comorbidities. Indeed, two-thirds of pneumococcal disease cases are found in 25% of the population with high-risk and at-risk conditions (25, 27). The reported odds ratios from different cohorts to develop IPD in patients with chronic respiratory diseases range between 1.3 and 4.7 compared to healthy individuals (28). These numbers are concerning, since exacerbations of chronic lung disease with concomitant pneumonia are associated with worse outcomes compared to exacerbations without pneumonia. The length of hospital stay is prolonged (7 vs. 4 days), admission rates to intensive care unit (ICU) are higher (12.5% vs. 7.7%; hazard ratio [HR]: 1.63), there is a higher need for mechanical/non-invasive ventilation (6.9%/9.7% vs. 3.3%/6.7%; HR: 2.10/1.45), and both 30-day mortality in first-time cases (12.1% vs. 8.3%; HR: 1.20) as well as mortality at second exacerbation (15% vs. 10.2.0%; HR: 1.14) are increased (29).

A study from 2005 estimated the incidences for pneumococcal infection at 8.8/100,000 in healthy adults and 62.9/100,000 in adults with chronic lung disease (30). How-ever, more recent data from England reported declining incidences probably due to the introduction of new vaccines in the previous decade (25). In Switzerland, pneumococcal conjugate vaccines (PCVs) are the only pneumococcal vaccines recommended since 2014. They are more effective than the previously used 23-valent pneumococcal polysaccharide vaccine (since 2014, PPV23 [Pneumovax®-23] is not recommended in Switzerland) due to many advantages (31, 32). PCVs elicit a T-cell dependent immune response, are effective also in children under the age of 2 years, generate immune memory, a booster effect, and herd immunity. In addition, they have a higher efficacy in risk-groups compared to the former PPV23 (32, 33). The efficacy of PCV13 vaccination (Prevenar 13®) was tested in the CAPiTA study (details see Table 1A) and suggests a number needed to vaccinate (NNV) of 1031 to prevent one case of CAP and a NNV of 2041 to prevent one case of IPD (33, 34). Since 2023, pneumococcal vaccination with a PCV is recommended for all individuals ≥ 65 years (in addition to children and adults with risk factors) by the FOPH, the Federal commission for Vaccinations, and also by international guidelines (8, 9, 35). Beyond PCV13 (33), the newer higher valency vaccines PCV15 (Vaxneuvance®) (36) and PCV20 (Prevenar 20®) (37) have been recently introduced in Switzerland and approved for use in individuals ≥65 years (35). High valency PCVs are important due to serotype replacement in recent years towards non-vaccine serotypes causing an increasing proportion and incidence of pneumococcal disease (38). In Switzerland, there is a considerable difference in the percentage of covered serotypes between the available vaccines in 2023 – 31% (PCV13), 40% (PCV15), and 68% (PCV20) respectively (39). Even though risk for pneumonia, exacerbation, and death are highly elevated in individuals with chronic lung diseases, the awareness for pneumococcal infections and the requirement for PCV vaccination is still rather low in Switzerland. The vaccination rate among individuals with asthma or chronic pulmonary disease was estimated at about 14.8% in 2020, and even lower at 9.6% in those aged 65 to 85 years, leaving many patients at risk unprotected (40).

Influenza vaccination

The influenza virus infects about 10-20% of the global population each year, causing 3-5 million hospitalizations annually. It is a leading cause for mortality, particularly in individuals at risk (41). Influenza also causes a high economical and individual burden in Switzerland, leading to a seasonal average of 4944 (standard error: ± 785) influenza-caused hospitalizations and direct medical costs of up to 77.3 million euros per season (42). A less appreciated danger of the virus lies in complications affecting the cardiovascular system (myocarditis, heart failure), the central nervous system (stroke, encephalitis) or other organs such as the kidneys and liver (acute kidney/liver injury). For example, it is estimated that up to 13% of hospitalized adult patients with influenza develop myocarditis (41). Another study reported acute cardiac injury within the first 3 days of influenza infection in 24% of high-risk patients (43, 44). Several meta-analyses and reviews have summarized evidence that a vaccination against influenza attenuates the severity of an influenza infection in individuals at risk and can prevent such complications. Evidence supporting flu vaccination is mostly based on case-control studies and cohort studies. Indeed, a meta-analysis identified only four randomized controlled trials (RCTs) including patients with COPD. Vaccination against influenza showed long-term benefits for patients with COPD regarding influenza-related respiratory infections, number of exacerbations, hospitalization rates, all-cause mortality, and respiratory mortality (45). Further, it was shown in a meta-analysis of RCTs (vaccination versus placebo) that influenza vaccination was able to decrease the rate of severe adverse cardiovascular events (RR: 0.64; 95% CI: 0.48-0.86) particularly in high-risk patients, giving a favorable NNV of 58 (46). Moreover, vaccination leads to a decrease in stroke occurrence (odds ratio [OR]: 0.81; 95% CI: 0.77-0.86), a reduction of mortality among stroke patients (OR: 0.50; 95% CI: 0.37-0.68) and a decrease of stroke occurrence in COPD (OR: 0.70; 95% CI: 0.61-0.81) (47). Additionally, all-cause mortality was reduced by 4.6% and hospitalization rates for pneumonia and influenza were reduced by 8.5% in individuals ≥65 years, and by 12.4% in individuals aged 50-64 years
(48, 49). Besides reducing direct health risks in a vulnerable population, influenza vaccination may also decrease antibiotic use due to prevention of CAP: Seasonal influenza vaccination averts about 1014.7 (95% CI: 803.3-1219.7) million defined daily doses of antibiotics (50).

Recent studies on the efficacy of different available influenza vaccines are summarized in table 1B. Notably, the US HAIVEN study reported an adjusted VE of 38% (95% CI: 17-53) against hospitalization for influenza-associated pneumonia, varying between strains (51). A multicenter study from the US showed a similar VE of 37% (95% CI: 27–46) against hospitalization, also reporting variations depending on strain and age (52). Different results were reported in another prospective study from the US, which found that the adjusted VE against influenza-related hospitalizations was 63.1% (95% CI: 43.8-75.8) in the pooled study population, and 68.2% (95% CI: 44.8-81.7) against hospitalization for exacerbation or acute respiratory infection (ARI) among those with congestive heart failure (CHF) or COPD (53). However, VE is estimated to have varied annually from 19% – 60% in the last 15 years, mainly due to differences in matching of vaccine strains with circulating strains (54). High-dose (HD) vaccines improve VE, particularly in seasons of low matching between the vaccine and the circulating virus strains and in older individuals or those at risk (55). Current Swiss recommendations emphasize the importance of influenza vaccination in individuals at risk, including those with chronic lung diseases (56). In Switzerland, the quadrivalent inactivated vaccines Fluarix Tetra® (57) and Vaxigrip Tetra® (approved from the age of 6 months) (58) are available and reimbursed for individuals ≥65 years and for all individuals with at least one risk factor (56). Recently, the HD quadrivalent influenza vaccine showed a relative VE of 64.4% regarding the prevention of hospitalizations due to influenza or pneumonia and of 48.9% regarding all-cause death, corresponding to a NNV of 346 and 311 respectively (see Table 1B for details) (59). Accordingly, the HD Efluelda® vaccine (60) is available in Switzerland for individuals ≥65 years and reimbursed in all individuals ≥75 years or ≥65 with at least one risk factor (56). Compared to the aforementioned pneumococcal vaccination, the rate of influenza vaccination among people with chronic lung diseases is higher in Switzerland, reaching 21.6% (95% CI: 18.68-24.85) in all age groups and 49.85% (95% CI: 41.61-58.09) in those aged ≥65 (61). For the coming influenza season 2024/2025, the US has decided on a transition back to the trivalent vaccine, as the B/Yamagata strain (included in the quadrivalent vaccines) is no longer circulating (62).

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination

Despite the decreasing media interest in SARS-CoV-2, the rates of the circulating virus are still high in 2024 (63). With the emergence of new variants, the mortality of a SARS-CoV-2 infection decreased, but is still 35% higher compared to an influenza infection (HR: 1.35; 95% CI: 1.10-1.66) (64). During earlier waves, the rate of severe COVID-19 was significantly higher in individuals who had a lung transplantation (OR: 4.62; 95% CI: 2.71-7.89) or chronic lung disease (OR: 2.11; 95% CI: 1.36-3.30) compared to the general population (65). Although severe COVID-19 cases have decreased in the Omicron era, individuals with asthma and COPD still had a significantly higher risk for developing severe COVID-19 (HR: 1.31; 95% CI: 1.10-1.55 and HR: 1.36; 95% CI: 1.12-1.66, respectively), but booster vaccinations reduced this risk (66). Administration of ≥3 doses of vaccination conferred a significantly reduced risk for a severe infection (OR: 0.35; 95% CI: 0.21-0.60) (65).

A study on the VE of SARS-CoV-2 vaccines is summarized in table 1C. In general, XBB.1.5 vaccines against omicron subvariants showed limited duration against preventing infection, with a VE of 52.2% (95% CI: 44.6-58.7) after 4 weeks, and 32.6% (95% CI: 28.1-36.8) after 10 weeks. However, VE against hospitalization and death was sustained over a longer period (67). Thus, protection against SARS-CoV-2 infection itself is only modest, but protection against severe COVID-19 leading to hospitalization remains high after vaccination. Accordingly, the FOPH currently recommends a SARS-CoV-2 vaccination for all individuals at risk, ideally with variant-adjusted vaccines (8). Similarly, also the GOLD-guidelines recommend a yearly COVID-19 vaccination for patients with COPD (9). Currently, the mRNA vaccines Comirnaty® (68) and Spikevax® (69) are available and approved for use in Switzerland. In general, the FOPH recommends the use of an mRNA vaccine targeting the current SARS-CoV-2 variants, regardless of previously administered vaccinations (70).

Varicella-zoster virus (VZV) vaccination

VZV causes varicella (chickenpox) and herpes zoster (shingles). Varicella typically manifests in childhood, characterized by a highly contagious vesicular rash and mild fever. Herpes zoster occurs due to reactivation of latent VZV, usually in older adults or immunocompromised individuals causing a painful, localized rash and severe nerve pain (postherpetic neuralgia) (71, 72). Worldwide, almost 84 million people are affected annually, leading to around 14,500 deaths per year. Although death rates appear to be rather low, the disease burden in affected people is high (72). The risk for developing herpes zoster is 24% higher in patients with asthma, and 41% higher in patients with COPD. This risk is further increased by the use of corticosteroid medication. Moreover, an exacerbation of COPD seems to be coupled with herpes zoster appearance and there is a higher risk for herpes zoster complications (postherpetic neuralgia, zoster ophthalmicus) in patients with asthma and COPD (73). Even though incidences are rising due to increased aging of the population, disease burden and death rates have decreased during the last decades. This is mostly attributable to vaccination, in particular with subunit vaccines (Shingrix®) (72, 74). Table 1D provides a summary on the VE of this recombinant VZV vaccination from two randomized controlled trials (RCTs). One study suggests a NNV of 35 (95% CI: 29-43) to prevent herpes zoster infection in ≥70-year-old patients, and a NNV of 32 (95% CI: 28-39) in ≥50-year-old patients (75). A 7-year follow-up on the cohort of patients ≥50 years reported a NNV of 51 (95% CI: 41-68) (76). In contrast, the protection of the live, attenuated vaccine waned over this time period (77). In Switzerland, vaccination with the recombinant subunit vaccine Shingrix® (78) is recommended for individuals aged ≥ 65 years, for individuals aged ≥ 50 years with severe asthma, COPD or immunodeficiency, and for individuals aged ≥ 18 years with severe immunosuppression (8).

Pertussis vaccination

Pertussis, or whooping cough, is a highly contagious disease characterized by severe coughing. It is caused by the bacterium Bordetella pertussis and affects about 50 million people worldwide every year, causing 300,000 deaths annually (79). Incidence in healthy people amounts to 0.5 per 100,000 and is significantly increased among patients with COPD (2.47 per 100,000; incidence rate ratio [IRR]: 4.94; 95% CI: 4.0-6.1;). Pertussis incidence in asthma patients is even higher with 3.35 per 100,000 (IRR: 6.70; 95% CI: 5.7-7.9) (79). Thus, specifically in patients with chronic lung disease, pertussis events cause a significant increase in health care resource utilization and direct medical costs (80). With the introduction of vaccines, mortality was ­significantly reduced, but there are still surges of the disease, which may be countered with up-to-date booster vaccinations (81). The surges may be attributable to the rather fast waning of protection from acellular vaccine as reported by a study on the Tdap-vaccines (tetanus, diphtheria, acellular pertussis) Boostrix® (82) and Adacel® (83). While VE was 75.3% (95% CI: 55.2-86.5) within 1 year, it decreased to 11.9% (95% CI: -11.1-30.1) within 4-5 years (84).
The FOPH currently recommends a basic pertussis vaccination in infants and boosters in childhood and adolescence. Moreover, a booster vaccination with either Boostrix® (82) or Adacel® (83) is recommended in adults who are in contact with infants and pregnant women. However, patients with COPD and asthma are not particularly mentioned (8). Also GOLD recommends a pertussis booster only in COPD patients who were not vaccinated in adolescence (9).

Future perspectives in Switzerland

In this section, we aim to provide a view of the future vaccination landscape in Switzerland, with a focus on new pneumococcus vaccines with higher serotype coverage and the first RSV vaccines already and soon to be available in Switzerland.

New pneumococcus vaccines

Currently, PCV15 and PCV20 are recommended for use in Switzerland (35). The US Federal Drug Administration (FDA) recently approved PCV21 for people aged ≥65 years, which represents a new concept of PCVs as it targets the majority of serotypes which currently affect adults. PCV21 does not include all pediatric serotypes, but it currently covers up to 85% of serotypes in those aged ≥65 years (85, 86). The U.S. Advisory Committee on Immunization Practices has already recommended this PCV21 as an option for adults. This recommendation also applies to individuals who had already received PCV13 in the past (86). Due to the coverage of 11 different serotypes, it is expected to bring benefits in terms of quality of life for the older population and a potential benefit for patients at risk for IPD (87). This approval is based on a recent study on the PCV21 vaccine in adults, which had proven a good tolerability and safety profile, while showing a non-inferior response to all included serotypes in comparison to previous PCV vaccinations covering fewer serotypes (88). Additionally, there are ongoing studies on a novel 24-valent PCV, which aims to increase even further serotype coverage (89).

Respiratory syncytial virus (RSV) vaccines

RSV is an RNA-virus, with its infections peaking in the winter months, causing a range of respiratory tract symptoms, and sometimes even pneumonia. Severe cases affect mostly infants, young children, and the elderly, leading to higher mortality in those age groups (90, 91). There are already two approved protein-based RSV vaccines available in Switzerland (92), and a third mRNA-based vaccine is currently in the approval process. Vaccination recommendations for older individuals and patients at high risk for complications, including those with chronic lung disease, have recently been published by the FOPH (93). Similarly, the GOLD guidelines recommend RSV vaccination for patients with COPD (9). This recommendation is based on the fact, that RSV is associated with more severe disease outcomes in comparison to influenza or SARS-CoV-2, even though less people are hospitalized with RSV (94). However, chronic lung diseases are among the major predictors for hospitalization of patients, infected with RSV (95). A recent modeling study reported a 2- to 4-fold increased risk of hospitalization for adults with COPD and RSV infection and a 1.5- to 3-fold increased risk for adults with asthma and RSV infection (96). Moreover, hospitalization due to RSV infection is associated with acute cardiac events, particularly in patients at risk (97).

In recent years, many RSV-vaccinations were studied in clinical trials, aiming to elicit an immune response against the RSV fusion protein F in its prefusion conformation (preF) (98). Besides the adjuvant RSVPreF3-antigen vaccination mentioned above (99), there is also a bivalent vaccine including the preF from both RSV A and B (100) as well as an mRNA vaccine (101) already available in some markets, albeit not approved in Switzerland yet. Several RCTs testing those different vaccines are summarized in table 1E. For the AS01E-adjuvanted RSV preF based candidate vaccine (RSVPreF3 OA) a NNV of 379 (95% CI: 247-811) was reported regarding the prevention of RSV-related lower respiratory tract disease (LRTD) (99). For the bivalent RSV preF based vaccine (bivalent RSVpreF) a NNV of 773 (95% CI: 429-3878) for RSV-associated LRTD with ≥2 signs/symptoms, and a NNV of 472 (95% CI: 284-1402) for RSV-associated ARI was reported (100). Lastly, the mRNA vaccine mRNA-1345 show-ed a NNV of 381 (95% CI: 264-683) against RSV-associated LRTD with ≥2 signs/symptoms and a NNV of 312 (95% CI: 209-616) for RSV-associated ARI (101). The immunization against preF was able to maintain a high VE against LRTD over a period of at least two to three seasons (102, 103). While the VE regarding severe RSV and LRTD is well studied in current RSV vaccines, data on VE regarding the prevention of hospitalizations is still limited. In the US, three RSV vaccines (one adjuvant RSVPreF3, one bivalent RSVpreF, and the mRNA vaccine) are already approved for adults ≥60 years, and the first safety data were recently presented (104). So far, injection site and systemic reactions were more frequently reported among patients receiving the adjuvant RSVPreF3 vaccine compared to the available bivalent RSVpreF. How-ever, the estimated rates for Guillain-Barré syndrome (GBS), which had been raised as a safety concern, were higher in people vaccinated with the bivalent vaccine (4.4 per 1 million administered doses) compared to the adjuvant one (1.8 per 1 million doses administered) (104). Even though GBS rates were more commonly reported than initially expected, the high efficacy in reducing severe RSV cases and exacerbations of chronic lung disease still suggests the importance of those RSV vaccines in at-risk patients.

Discussion

In summary, the Swiss vaccination plan provides specific recommendations for the vaccination of individuals at risk, including patients with chronic lung diseases (8). Still, the vaccination rate among patients with chronic lung diseases, particular for S. pneumoniae, remains low in Switzerland, highlighting the need for more awareness in clinics and among general practitioners (40). Moreover, due to serotype replacement in pneumococcal disease observed in recent years, recommendation for newer PCVs covering more serotypes, especially for individuals at risk, should be made (38). This may include the PCV21 in the near future, as it has recently been approved by the FDA (86). While the GOLD guidelines have already recommended RSV and pertussis vaccinations for patients with COPD, the recommendations regarding RSV were only recently anchored in the Swiss recommendations (8, 9, 12). This recent update reflects the potential severity of an RSV infection for patients with chronic lung diseases (94). Indeed, the FDA has already approved three RSV vaccines in the last years (104). Also, Switzerland has recently introduced two vaccines on the market for adults aged ≥60 years (93). Several impor-tant questions remain regarding RSV vaccination, such as the efficacy of repeated vaccination, duration of response and most importantly the effectiveness in populations with comorbidities (105). Moreover, safety and immunogenicity of coadministration with for example influenza vaccines are still under investigation. Current studies suggest that coadministration is probably acceptable, even though a slight reduction in RSV antibody responses was observed (106). In general, even though RSV vaccinations are associated with certain risks such as GBS, those are outweighed by the successful prevention of exacerbations and cardiovascular events in individuals at risk (107). This goes in line with the protective properties of for example influenza and S. pneumoniae vaccines, which have shown to reduce the risk for myocardial infarction and cardiovascular additionally to pulmonary exacerbations (107).
Our review has several limitations. It is not a systematic review and meta-analysis, as we incorporated only selected studies evaluating the NNV and VE of various vaccin-es recommended for patients with chronic lung diseases. Furthermore, most of those vaccination studies were not explicitly performed in patients with chronic lung diseases. While some of the mentioned studies assessed the percentage of patients with chronic lung diseases, COPD and asthma in particular, there was almost no record of ILD. In general, a lot of the recommendations for vaccination in patients with chronic lung diseases focus on COPD (9). Although there are some studies on the role of infection-driven exacerbations in asthma, data on the impact of res-piratory infections on the exacerbation of ILD are scarce (21).

In conclusion, aiming for a higher vaccination rate among individuals with chronic pulmonary diseases is crucial in preventing exacerbations and thus morbidity and mortality in this vulnerable population. The introduction of new and more effective vaccines, such as updated PCVs and RSV vaccines in Switzerland as well as the constant variant-adjustment of influenza and SARS-CoV2 vaccines will be pivotal in ensuring protection in comorbid patients in the future. Strategies to improve vaccination rates may include the identification of drivers of and barriers to vaccinations to make informed decisions, as well as patient education and training for healthcare providers and national authorities (108).

Abbreviations
ARI acute respiratory illness
CAP community acquired pneumonia
CI confidence interval
CHF congestive heart failure
COPD chronic obstructive pulmonary disease
COVID-19 coronavirus disease 19
FEV1 Forced Expiratory Volume in one second
FOPH Swiss federal office of public health
GOLD Global initiative for chronic obstructive lung disease
HD high dose
HMPV human metapneumovirus
HR hazard ratio
ILD interstitial lung disease
IPD invasive pneumococcal disease
IRR incidence rate ratio
LRTD lower respiratory tract disease
mRNA-1345 mRNA-based RSV vaccine encoding the stabilized RSV prefusion F glycoprotein
NC not calculable
NE not estimable
NEDSS Nebraska Electronic Disease Surveillance System
NESIIS Nebraska State Immunization Information System
NS not specified
NNV number needed to vaccinate (rounded to unit)
OR odds ratio
PBO placebo»
PCV pneumococcal conjugate vaccine
PPV pneumococcal polysaccharide vaccine
PY person years
QIV quadrivalent influenza vaccine
RCT randomized controlled trial
RR risk ratio
RSV respiratory syncytial virus
RSVpreF bivalent RSV prefusion F protein-based vaccine
RSVPreF3 OA AS01E-adjuvanted RSV prefusion F protein–based vaccine
RZV glycoprotein E (gE)-based adjuvanted recombinant zoster vaccine
SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
SD standard dose
VE vaccine efficacy
VZV varicella zoster virus